Read the Daily News for highlights from Day 2.
Dan Zandberg, MD, and colleagues from UPMC Hillman Cancer Center presented the results of their prospective phase II study of personalized immunotherapy that seeks to enhance treatment outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), whose disease has progressed on anti-PD-1 or anti-PD-L1 monoclonal antibody (mAb) therapy.
As the incidence of human papillomavirus-positive (HPV+) oropharyngeal cancer (OPC) has increased rapidly in North America, improved screening and early detection has been a significant focus of research.
Chemoradiation with concurrent cisplatin is standard treatment for patients with locally advanced head and neck squamous cell cancer (LA HNSCC). However, many patients are not candidates for cisplatin; treatment options for these patients are limited.
For many years, radiation therapy (RT) has been the main treatment for unresectable, locally advanced basal cell carcinoma (BCC). Patients whose tumors are not controlled can experience devastating cancer-related problems such as bleeding and malodor from fungating tumors that are locally destructive.
Annie Chan, MD, and Rahul Paul, PhD, from the Department of Radiation Oncology at Massachusetts General Hospital, together with their otolaryngology colleague Jeremy Richmon, MD, at the Massachusetts Eye and Ear Infirmary reported on utilizing machine learning and deep learning algorithms that incorporate perinodal microenvironment to improve the performance of their AI model in predicting for extranodal extension (ENE) in patients with oropharyngeal cancer.
Yesterday, Carmen Guerra, MD, MSCE, presented an engaging keynote: “Overcoming Structural Barriers to Diverse Representation and Clinical Trials.” Kelly Malloy, MD, of University of Michigan, introduced Dr. Guerra, sharing that Dr. Guerra’s perspective is borne of many critical roles, including as the Ruth C. and Raymond G. Perelman Professor of Medicine at the University of Pennsylvania. She is also a practicing internist and the Associate Director of Diversity and Outreach for the Abramson Cancer Center, where she helps to design and implement interventions to increase the participation of underrepresented populations.
The Society for Immunotherapy of Cancer’s (SITC) Certificate in Cancer Immunotherapy program is designed to offer physicians and health care providers the knowledge and skills to deliver effective care to cancer patients being treated with immunotherapy.
Generic drug shortages are a crisis for cancer care in the U.S. Currently, 15 cancer-related drugs are in short supply. To help address this emergency, the American Society of Clinical Oncology and the Association for Clinical Oncology (collectively ASCO) are working to help mitigate the current crisis and prevent similar situations in the future.
